Plasma Dilution / Therapeutic Plasma Exchange — Gene Therapy & Genetic Interventions
Removal and replacement of aged plasma factors via therapeutic plasma exchange to rejuvenate tissues.
Overview
Therapeutic plasma exchange (TPE) / plasma dilution involves removing aged plasma and replacing it with saline and albumin, effectively diluting pro-aging circulating factors. Irina and Michael Conboy's research at UC Berkeley demonstrated that a single plasma dilution procedure in aged mice rejuvenated muscle, liver, brain, and other tissues as effectively as young blood transfusion (parabiosis), suggesting that diluting old factors is more important than adding young factors. Human TPE is already FDA-approved for autoimmune conditions. Dobri Kiprov has conducted observational studies of TPE for anti-aging in humans.
Indications
- Age-related tissue decline (investigational)
- Reduction of pro-aging circulating factors
- Immune system rejuvenation
- Neuroinflammation reduction
- Autoimmune conditions (FDA-approved indication)
Mechanism of Action
Apheresis device separates and removes aged plasma containing elevated pro-aging factors (CCL11, B2M, TGF-beta)
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Therapeutic Plasma Exchange | 1-1.5 plasma volumes | Single session or series of 3-5 | Replace with 5% albumin + saline |
Safety & Contraindications
- TPE is a well-established medical procedure with known risks
- Hypovolemia, electrolyte imbalances, and citrate toxicity possible during procedure
- Coagulation factor depletion (replaced within 24-48 hours)
- Allergic reactions to albumin replacement solution
- Vascular access complications
- Anti-aging use is off-label; not FDA-approved for aging indications